Biocon’s arm launches Yesintek (ustekinumab-kfce) in United States

25 Feb 2025 Evaluate

Biocon’s subsidiary -- Biocon Biologics has launched Yesintek (ustekinumab-kfce) in the United States and is one of the first Stelara (ustekinumab) biosimilar market entrants in the country. Yesintek is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases. 

Yesintek will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

378.60 0.80 (0.21%)
16-Feb-2026 09:23 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1712.20
Dr. Reddys Lab 1271.15
Cipla 1340.20
Zydus Lifesciences 911.85
Lupin 2224.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×